Tag Archives: Patents

FDA Announces First-Ever Patient Engagement Advisory Committee

Recently, the FDA announced the formation of the Patient Engagement Advisory Committee (PEAC) and requested public comments on what topics the committee should consider, which are due November 20th. FDA also published three requests for nominations to serve on the committee, including one for industry members which is due October 21st.


CLSA in Politico: On Patents, Life Sciences Groups Voice ‘Disappointment’ With Issa

CLSA President & CEO Sara Radcliffe and Biocom President & CEO Joe Panetta respond to comments Rep. Issa made in a Politico Pro, alleging that opponents of pending patent litigation reform legislation (H.R. 9) have spread “misinformation” about the bill. Issa’s remarks are dismissive of concerns of life sciences sector in San Diego and across California


CLSA Efforts to Protect Patents Gain Momentum

CLSA is actively opposing H.R. 9, the so-called Innovation Act, legislation that contains patent litigation-related provisions that would threaten the ability of biomedical innovators to enforce their patents and fund continued R&D by making it more difficult, time-consuming and expensive to enforce legitimate and important IP rights.




CLSA Continues to Engage with California Delegation to Protect Patent Rights, Oppose H.R. 9

CLSA is actively opposing H.R. 9, the so-called Innovation Act, legislation that contains patent litigation-related provisions that would threaten the ability of biomedical innovators to enforce their patents and fund continued R&D by making it more difficult, time-consuming and expensive to enforce legitimate and important IP rights. We continue to work stakeholders and members of the California congressional delegation to advocate for changes to the legislation that would both strengthen patent protections and curb abusive litigation practices by “patent trolls” for all patent holders and industry sectors.